Amanda M Johnson1, W Scott Harmsen2, Satimai Aniwan1,3, William J Tremaine1, Barham K Abu Dayyeh1, Edward V Loftus1. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. 2. Biostatistics and Informatics, Mayo Clinic, Rochester, MN, USA. 3. Division of Gastroenterology, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Abstract
BACKGROUND AND AIMS: There remains a historical misconception that inflammatory bowel disease [IBD] patients are underweight. However, recent data suggest rates of obesity in IBD parallel to those of the general population. The impact obesity has on the natural history of IBD is unclear. We aimed to determine obesity rates at the time of IBD diagnosis in a population-based cohort of ulcerative colitis [UC] patients. METHODS: Chart review was performed on patients diagnosed with UC over 1970-2010. Data were collected on demographics, body mass index [BMI], disease characteristics, IBD-specific hospitalisations, intestinal resection, and corticosteroid use. The proportion of patients who were obese at the time of their diagnosis was evaluated over time, and survival free of IBD-related complications was assessed using Kaplan-Meier survival analysis. RESULTS: A total of 417 adults were diagnosed with UC over 1970-2010, 55.4% of whom were classified as either overweight [34.8%] or obese [20.6%]. The prevalence of obesity increased 2-3-fold over the 40-year study period. Obese patients had a 72% increased risk of hospitalisation (hazard ratio [HR],1.72; 95% confidence interval [CI], 1.10-2.71; p = 0.018) when compared with normal weight patients. Additionally, with each incremental increase in BMI by 1 kg/m2, the risk of hospitalisation increased by 5% [HR,1.05; 95% CI, 1.01-1.08; p = 0.008] and risk of corticosteroid use increased by 2.6% [HR,1.026; 95% CI, 1.00-1.05; p = 0.05]. CONCLUSIONS: The prevalence of obesity in the UC population is increasing and may have negative prognostic implications, specifically regarding risk of future hospitalisation and corticosteroid use. Additional prospective studies are necessary to more clearly define these associations.
BACKGROUND AND AIMS: There remains a historical misconception that inflammatory bowel disease [IBD] patients are underweight. However, recent data suggest rates of obesity in IBD parallel to those of the general population. The impact obesity has on the natural history of IBD is unclear. We aimed to determine obesity rates at the time of IBD diagnosis in a population-based cohort of ulcerative colitis [UC] patients. METHODS: Chart review was performed on patients diagnosed with UC over 1970-2010. Data were collected on demographics, body mass index [BMI], disease characteristics, IBD-specific hospitalisations, intestinal resection, and corticosteroid use. The proportion of patients who were obese at the time of their diagnosis was evaluated over time, and survival free of IBD-related complications was assessed using Kaplan-Meier survival analysis. RESULTS: A total of 417 adults were diagnosed with UC over 1970-2010, 55.4% of whom were classified as either overweight [34.8%] or obese [20.6%]. The prevalence of obesity increased 2-3-fold over the 40-year study period. Obese patients had a 72% increased risk of hospitalisation (hazard ratio [HR],1.72; 95% confidence interval [CI], 1.10-2.71; p = 0.018) when compared with normal weight patients. Additionally, with each incremental increase in BMI by 1 kg/m2, the risk of hospitalisation increased by 5% [HR,1.05; 95% CI, 1.01-1.08; p = 0.008] and risk of corticosteroid use increased by 2.6% [HR,1.026; 95% CI, 1.00-1.05; p = 0.05]. CONCLUSIONS: The prevalence of obesity in the UC population is increasing and may have negative prognostic implications, specifically regarding risk of future hospitalisation and corticosteroid use. Additional prospective studies are necessary to more clearly define these associations.
Authors: S Baron; D Turck; C Leplat; V Merle; C Gower-Rousseau; R Marti; T Yzet; E Lerebours; J-L Dupas; S Debeugny; J-L Salomez; A Cortot; J-F Colombel Journal: Gut Date: 2005-03 Impact factor: 23.059
Authors: Hamed Khalili; Ashwin N Ananthakrishnan; Gauree G Konijeti; Leslie M Higuchi; Charles S Fuchs; James M Richter; Andrew T Chan Journal: Inflamm Bowel Dis Date: 2015-02 Impact factor: 5.325
Authors: Simon S M Chan; Robert Luben; Anja Olsen; Anne Tjonneland; Rudolf Kaaks; Birgit Teucher; Stefan Lindgren; Olof Grip; Timothy Key; Francesca L Crowe; Manuela M Bergmann; Heiner Boeing; Göran Hallmans; Pontus Karling; Kim Overvad; Domenico Palli; Giovanna Masala; Hugh Kennedy; Fiona vanSchaik; Bas Bueno-de-Mesquita; Bas Oldenburg; Kay-Tee Khaw; Elio Riboli; Andrew R Hart Journal: Am J Gastroenterol Date: 2013-01-15 Impact factor: 10.864
Authors: Raina Shivashankar; William J Tremaine; W Scott Harmsen; Edward V Loftus Journal: Clin Gastroenterol Hepatol Date: 2016-11-14 Impact factor: 11.382
Authors: Siew C Ng; Hai Yun Shi; Nima Hamidi; Fox E Underwood; Whitney Tang; Eric I Benchimol; Remo Panaccione; Subrata Ghosh; Justin C Y Wu; Francis K L Chan; Joseph J Y Sung; Gilaad G Kaplan Journal: Lancet Date: 2017-10-16 Impact factor: 79.321
Authors: Satimai Aniwan; William J Tremaine; Laura E Raffals; Sunanda V Kane; Edward V Loftus Journal: J Crohns Colitis Date: 2018-01-24 Impact factor: 9.071
Authors: Mohamed A Abd-El-Aziz; Martin Hübner; Nicolas Demartines; David W Larson; Fabian Grass Journal: Nutrients Date: 2022-02-22 Impact factor: 5.717